August 2006
Worldwide Biotech;Aug2006, Vol. 18 Issue 8, p6
Trade Publication
Reports on a negative opinion received by biopharmaceutical company BioPartners of Switzerland from the European Medicine Agency's Committee on Medicinal Products for Human Use. Reaction of the company to the ruling; Basis of the ruling; Marketing approval received by the company for its Valtropin product.


Related Articles

  • BioPartners submits an application for approval of Valtropin in Europe.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p12 

    Reports that BioPartners GmbH, a global biopharmaceuticals company, has submitted a marketing authorization application to the European Medicines Evaluation Agency for Valtropin. Formulation of Valtropin; Safety and efficacy of the drug; Significance on the approval of the drug.

  • First generic biologics finally approved. Sheridan, Cormac // Nature Reviews Drug Discovery;Jun2006, Vol. 5 Issue 6, p445 

    Decision ends years of fierce debate on follow-on protein products, but won't lead to an opening of the approval floodgates

  • Negative opinion on biosimilar drug.  // Pharmaceutical Technology Europe;Sep2006, Vol. 18 Issue 9, p18 

    The article reports that Swiss firm BioPartners SA has been unsuccessful in gaining EMEA approval for its second biosimilar product in Europe. The Committee for Medicinal Products Human Use gave a negative opinion on the drug Alpheon, a biosimilar of Roche's Roferon-A, an injectable interferon...

  • NEWS IN BRIEF.  // Pharmaceutical Technology Europe;Jan2002, Vol. 14 Issue 1, p8 

    Presents technology news briefs in the pharmaceutical industry in Europe as of January 2002. Design of the headquarters of Pfizer Inc.; Contract awarded to Invensys Process Systems; Result of a study on the chemical and pharmaceutical industry of Switzerland; Terms of an agreement between...

  • OTHER NEWS TO NOTE.  // BioWorld Today;2/23/2009, Vol. 20 Issue 34, p2 

    This section offers news briefs on the biopharmaceutical industry. After helping MBiotec GmbH to secure a licensing contract with HZI, Ascenion GmbH plans to take an equity position in MBiotec. Biopartners GmbH will ask the European Medicines Agency to reassess the company's interferon beta-1a,...

  • Applications Update.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p12 

    The article reports an update on various applications filed by several pharmaceutical industry in the U.S. Genentech refiles a license application for Avastin in combination with paclitaxel chemotherapy for untreated patients with metastatic breast cancer. Basilea Pharmaceutica has applied for...

  • CLINIC ROUNDUP.  // BioWorld Today;6/12/2009, Vol. 20 Issue 112, p5 

    This section offers news briefs on the pharmaceutical industry. Aradigm Corp. has announced that data from a Phase I study of healthy subjects and a Phase IIa study of cystic fibrosis patients have shown similar pharmacokinetics for its inhaled liposomal ciprofloxacin. Positive Phase III study...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Oct2007, Vol. 6 Issue 10, p6 

    The article offers news briefs related to multiple sclerosis drug in the U.S. Biogen Idec Inc. and Elan Corp. said that patients with Tysabri in a Phase III multiple sclerosis study showed a significant improvement in health-related quality-of-life measures when compared to placebo. Swiss...

  • Marketers are `laughing at the FDA'. Dickinson, James G. // Medical Marketing & Media;Aug99, Vol. 34 Issue 8, p14 

    Focuses on the United States Food & Drug Administration's (FDA) regulation of drug marketing in the country. Reasons for the drug industry's apparent disregard of drug marketing regulations; Proposals for the FDA Division of Drug Marketing and Communications to enhance its effectiveness and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics